FcγRIII in ITP: it ain't over 'til it's over

Blood. 2016 Jan 7;127(1):11-2. doi: 10.1182/blood-2015-11-678680.

Abstract

In this issue of Blood, Yu et al describe a novel anti–Fcγ receptor III (FcγRIII)-albumin fusion protein that inhibits the development of thrombocytopenia in a murine model of immune thrombocytopenia (ITP).1 The unique aspect of this protein is that it blocks FcγRIII-mediated uptake of antibody-coated platelets without activating FcγRIII and the associated inflammatory response.

Publication types

  • Comment

MeSH terms

  • Albumins / immunology*
  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Female
  • Humans
  • Immunoglobulin Fc Fragments / immunology*
  • Purpura, Thrombocytopenic, Idiopathic / therapy*
  • Receptors, IgG / antagonists & inhibitors*
  • Receptors, IgG / immunology*
  • Recombinant Fusion Proteins / immunology*

Substances

  • Albumins
  • Antibodies, Monoclonal
  • Immunoglobulin Fc Fragments
  • Receptors, IgG
  • Recombinant Fusion Proteins

Associated data

  • PDB/3SGJ